Assessment includes the person’s symptoms, medication history and prolactin testing interpreted under suitable conditions. Clinicians consider pregnancy where relevant, thyroid or other medical causes, and whether additional investigation is needed. The degree and persistence of elevation help guide the response, but no single number replaces clinical context.
Hyperprolactinaemia means an elevated level of prolactin, a hormone produced by the pituitary gland. Dopamine normally restrains prolactin release, so some D2-blocking medicines can increase it. Other physiological, medical and medication causes also exist. A raised result requires interpretation in context rather than automatic attribution to an antipsychotic or a single disease.
Management may involve monitoring, reviewing the antipsychotic regimen or specialist input. Options depend on the drug, psychiatric stability, physical findings and the person’s priorities. Treatments that influence dopamine can have psychiatric implications, so self-medication is inappropriate. Follow-up should establish whether symptoms and laboratory findings improve while mental health remains supported. Clear communication is essential because people may otherwise stop treatment to escape distressing effects. An agreed plan recognises hormonal and sexual health as legitimate parts of effective care rather than secondary concerns that must simply be tolerated.
The plan should specify which question is being addressed: confirming the result, identifying a cause, treating symptoms or evaluating longer-term consequences. Different questions may require different investigations or specialists. Clear follow-up helps prevent an abnormal value being repeatedly recorded without resolution. The person’s experience and psychiatric stability remain part of the decision rather than being separated from the hormonal concern.
Further reading: DailyMed prescribing information (1); DailyMed prescribing information (2).
Comments are closed, but trackbacks and pingbacks are open.